Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Clin Densitom. 2011 Jul-Sep;14(3):220-2. doi: 10.1016/j.jocd.2011.05.008.

Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

Author information

  • 1Academic Unit of Bone Metabolism, University of Sheffield, Sheffield S5 7AU, UK. e.v.mccloskey@shef.ac.uk

Abstract

The best indirect evidence that increased bone turnover contributes to fracture risk is the fact that most of the proven therapies for osteoporosis are inhibitors of bone turnover. The evidence base that we can use biochemical markers of bone turnover in the assessment of fracture risk is somewhat less convincing. This relates to natural variability in the markers, problems with the assays, disparity in the statistical analyses of relevant studies and the independence of their contribution to fracture risk. More research is clearly required to address these deficiencies before biochemical markers might contribute a useful independent risk factor for inclusion in FRAX(®).

Copyright © 2011. Published by Elsevier Inc.

PMID:
21810528
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk